GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
30 déc. 2022 08h00 HE
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
Bioxytran Interview at the Emerging Growth Conference
12 déc. 2022 09h45 HE
|
BIOXYTRAN, INC.
Wednesday, December 14, 2022 1:45pm –2:15pm ESTDiscussion of Clinical Trial Results BOSTON, MASSACHUSETTS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a...
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
08 déc. 2022 07h00 HE
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and...
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million
07 déc. 2022 08h35 HE
|
Palisade Bio, Inc.
Proceeds extend cash runway to fund operations into early 2024 Carlsbad, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company...
Palisade Bio Regains Compliance with Nasdaq Listing Requirements
01 déc. 2022 14h44 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
22 nov. 2022 08h35 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for avoidance of acute and chronic...
Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
18 nov. 2022 08h05 HE
|
Palisade Bio, Inc.
Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries Well-versed with LB1148 -...
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
17 nov. 2022 08h30 HE
|
Palisade Bio, Inc.
Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI) tissues and accelerate the time to the return of normal GI function Carlsbad, CA, Nov. 17,...
Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 08h45 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc., (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Bioxytran Scientific Advisor Releases New Book on Brain Metabolism
25 oct. 2022 07h00 HE
|
BIOXYTRAN, INC.
The book contains all aspects of brain energy metabolism and other physiological functions related to Cortical Spreading Depression which is the essence of how the brain consumes oxygen. BOSTON,...